Genentech, a member of the Roche Group headquartered in South San Francisco, California, will invest approximately $750 million to build a device fill-finish manufacturing facility at its 75-acre campus in Hillsboro, Oregon.

The project will add end-to-end device filling capabilities and is expected to double the size of the existing facility. The capital expenditure is anticipated to create 250 high-wage manufacturing jobs and about 200 construction jobs, with commercial operations planned to begin in 2031.

The facility will manufacture drug delivery devices including prefilled syringes and autoinjectors. It will support both high- and low-volume filling across Genentech’s portfolio, providing flexibility as manufacturing requirements change.

The Hillsboro campus, established in 2006, currently supports production across therapeutic areas including oncology, immunology, and neurology. The new facility will add device filling to the site’s existing manufacturing capabilities and expand Genentech’s U.S. production network.

The investment follows Genentech’s recent topping-out milestone for a roughly $2 billion biomanufacturing facility in Holly Springs, North Carolina. That plant is expected to produce treatments for metabolic conditions and incorporate automation, robotics, and digital manufacturing technologies.

Roche and Genentech said their U.S. network includes 13 manufacturing sites and 15 research and development sites across eight states. The latest addition is part of a previously announced $50 billion commitment to U.S. R&D and production infrastructure.